Bellerophon Therapeutics (NASDAQ:BLPH) Rating Lowered to Hold at Zacks Investment Research

Bellerophon Therapeutics (NASDAQ:BLPH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Monday, Zacks.com reports.

According to Zacks, “Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company’s product pipeline consists of INOpulse and BCM which are in different clinical stage. Bellerophon Therapeutics LLC is based in Hampton, New Jersey. “

Shares of Bellerophon Therapeutics stock opened at $4.08 on Monday. Bellerophon Therapeutics has a 1-year low of $3.79 and a 1-year high of $14.09. The firm’s fifty day simple moving average is $4.31. The company has a market cap of $38.78 million, a P/E ratio of -1.47 and a beta of -0.58.

Bellerophon Therapeutics (NASDAQ:BLPH) last announced its earnings results on Monday, May 10th. The biotechnology company reported ($0.58) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.71) by $0.13. As a group, equities research analysts predict that Bellerophon Therapeutics will post -2.69 EPS for the current year.

Large investors have recently bought and sold shares of the company. GSA Capital Partners LLP increased its holdings in shares of Bellerophon Therapeutics by 6.7% in the 1st quarter. GSA Capital Partners LLP now owns 63,566 shares of the biotechnology company’s stock valued at $330,000 after purchasing an additional 3,977 shares during the period. BlackRock Inc. lifted its position in Bellerophon Therapeutics by 2.3% in the 1st quarter. BlackRock Inc. now owns 321,782 shares of the biotechnology company’s stock worth $1,670,000 after buying an additional 7,165 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Bellerophon Therapeutics by 261.4% during the 4th quarter. JPMorgan Chase & Co. now owns 10,701 shares of the biotechnology company’s stock valued at $72,000 after buying an additional 7,740 shares during the period. DAVENPORT & Co LLC boosted its stake in shares of Bellerophon Therapeutics by 10.9% during the 1st quarter. DAVENPORT & Co LLC now owns 98,975 shares of the biotechnology company’s stock valued at $514,000 after buying an additional 9,750 shares during the period. Finally, LPL Financial LLC purchased a new position in shares of Bellerophon Therapeutics during the 4th quarter valued at $67,000. Institutional investors own 22.01% of the company’s stock.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.

Further Reading: Does the Step Transaction Doctrine Affect a Backdoor Roth IRA?

Get a free copy of the Zacks research report on Bellerophon Therapeutics (BLPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.